ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

NCI Plans Progress Review In Lymphoma This Year.

March 10, 2000

NCI to Study Vasectomy And Prostate Cancer: DCE Concepts OK’d

July 2, 1993

Two Studies Suggest Positive HPV Status Can Indicate Improved Patient Outcomes

February 28, 2014

Buenos Aires Academy Denies Argentina Prosecutes Scientist

July 28, 1978

Low Total Cholesterol Linked To Higher Risk Of Cancer; Higher HDL Associated With Decreased Risk Of Cancer

November 27, 2009

Cancer Policy: Coffey Letter Lists Research Initiatives That Justify Increase

December 19, 1997